Genovis AB (publ.) (STO:GENO)

Sweden flag Sweden · Delayed Price · Currency is SEK
28.10
-0.90 (-3.10%)
Jul 11, 2025, 12:51 PM CET
-3.10%
Market Cap 1.90B
Revenue (ttm) 123.87M
Net Income (ttm) 23.63M
Shares Out 65.47M
EPS (ttm) 0.36
PE Ratio 80.34
Forward PE 61.05
Dividend n/a
Ex-Dividend Date n/a
Volume 15,324
Average Volume 44,452
Open 29.00
Previous Close 29.00
Day's Range 27.95 - 29.30
52-Week Range 17.10 - 31.25
Beta 1.91
RSI 60.10
Earnings Date Aug 12, 2025

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 32
Stock Exchange Nasdaq Stockholm
Ticker Symbol GENO
Full Company Profile

Financial Performance

In 2024, Genovis AB (publ.)'s revenue was 131.32 million, a decrease of -17.44% compared to the previous year's 159.07 million. Earnings were 32.92 million, a decrease of -46.48%.

Financial Statements

News

Genovis AB (OSTO:GENO) Q3 2024 Earnings Report Preview: What to Expect

Genovis AB (OSTO:GENO) Q3 2024 Earnings Report Preview: What to Expect

8 months ago - GuruFocus